

REMARKS

Claims 1-10, 14-18, 25-29, 32-37, 41-44, 46, and 48-50 are pending. Claims 1 and 18 have been amended. Support for the amendment to claim 1 is found on page 11, lines 15-29, and page 31, line 22 to page 34, line 22, *inter alia*. Claims 49 and 51-56 have been added, as supported by page 5, lines 24-31 and page 30, lines 15-23, and the examples. Following entry of the amendments, claims 1-10, 14-18, 25-29, 32-37, 41-44, 46, and 48-56 will be pending.

Applicant respectfully requests that the foregoing amendments be made prior to further examination of the present application, and respectfully requests reconsideration of the present application in view of the foregoing amendments and the reasons that follow. This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, is presented, along with appropriate defined status identifiers.

Prior rejections have been withdrawn. Three new rejections have been stated.

Claims 1-3, 5-10, 14-18, 25-29, 32-37, 41-44 and 48-50 are rejected under Section 102(e) based on US 2004/0219203. The subject matter relating to veterinary applications that is disclosed but not claimed in US 2004/0219203, filed jointly by Dr. Goldenberg and others, was invented by Dr. Goldenberg. Forwarded herewith is a declaration under 37 CFR 1.132 by Dr. Goldenberg that he invented the veterinary subject matter that is disclosed in US 2004/0219203 and relied on in the rejection. *In re DeBaun*, 687 F.2d 459, 214 USPQ 933 (CCPA 1982). Reconsideration and withdrawal of this rejection is respectfully requested.

Claims 1-3, 5, 8-10, 15-28, 25, 26, 32, 33, 37, 41-43, 46 and 48 are rejected under Section 102(e) based on US 2001/0018041, and claims 1-3, 5, 8-10, 15-28, 25, 26, 32, 33, 37, 41-43, 46 and 48-50 under Section 103(a) based on US 2001/0018041 in view US 2004/0219203. US 2001/0018041 discloses the treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Applicant has amended the present claims to recite a method for treating a B-cell disorder in a horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat, consisting of administering a therapeutic composition consisting of at least one anti-CD20, anti-CD74 or anti-HLA-DR antibody component and, optionally, a cytotoxic drug, an immunosuppressive drug, or an immunomodulator, in a pharmaceutically acceptable carrier. The present claim does not encompass treatment with anti-CD40L antibodies. Furthermore, treatment with anti-CD40L antibodies is a necessary feature of the

treatment regimen disclosed in US 2001/0018041, and therefore a treatment regimen that does not include treatment with anti-CD40L would not have been obvious based on the cited documents. Reconsideration and withdrawal of this rejection is respectfully requested.

If there are any problems with this response, or if the examiner believes that a telephone interview would advance the prosecution of the present application, Applicant's attorney would appreciate a telephone call. In view of the foregoing, it is believed none of the references, taken singly or in combination, disclose the claimed invention. Accordingly, this application is believed to be in condition for allowance, the notice of which is respectfully requested.

Respectfully submitted,

ROSSI, KIMMS & McDOWELL LLP

JANUARY 11, 2008

DATE

/BARBARA A. McDOWELL/

BARBARA A. McDOWELL

REG. NO. 31,640

P.O. BOX 826

ASHBURN, VA 20146-0826

703-726-6020 (PHONE)

703-726-6024 (FAX)